Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study.

Departments of Respiratory Medicine, Surgery, and Obstetrics and Gynecology, Kuopio University Hospital, Research Institute of Public Health, University of Kuopio, Kuopio, Finland.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 04/1999; 159(4 Pt 1):1179-85.
Source: PubMed

ABSTRACT It is not known whether asthma constitutes a risk factor for osteoporosis or what the impact is of inhaled corticosteroids on bone mineral density (BMD). The study population (n = 3,222) was a random stratified sample from the Kuopio Osteoporosis Study, which included all women 47 to 56 yr of age residing in Kuopio Province, Eastern Finland. Spinal and femoral BMDs were measured using dual-energy X-ray absorptiometry. The BMD values of 119 asthmatics were cross-sectionally compared with those of 3,103 nonasthmatics. Of the 119 asthmatic women, 28 had not used corticosteroids, 65 had used oral corticosteroids, and 26 had used only inhaled corticosteroids. The asthmatics with no hormone replacement therapy (HRT) (n = 83) had lower mean spinal and femoral BMD value than did the corresponding nonasthmatics (spinal BMD, 1.083 +/- 0.150 [SD] versus 1.128 +/- 0.160 g/cm2, p < 0.05; femoral BMD, 0.894 +/- 0.112 [SD] versus 0.929 +/- 0.128 g/cm2, p < 0.05). Although BMDs were not significantly decreased in the asthmatics who had used inhaled corticosteroids, the duration of use correlated negatively with spinal BMD and was also associated with spinal BMD in multiple regression analysis. In perimenopausal women, asthma is associated with decreased bone density. This may be due to the corticosteroids rather than to the disease itself. However, HRT appears to be protective against bone loss also in asthmatics.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The chronic use of glucocorticoids results in osteoporosis. Several sets of guidelines have been published on the management of glucocorticoid induced osteoporosis (GIO). These guidelines vary on their focus and highlight different aspects of the current concepts in the management of GIO. In this current article, we summarize recent guidelines for management of GIO and highlight similarities and differences as well as address some of the controversies generated by these guidelines.
    Current Osteoporosis Reports 10/2013; 11(4). DOI:10.1007/s11914-013-0170-3
  • [Show abstract] [Hide abstract]
    ABSTRACT: Summary The effect of inhaled corticosteroid on bone mineral density (BMD) was investigated in 44 asthmatic patients after median treatment duration of 6.5 years. Compared with controls, BMD decreased only in patients aged p = 0.013) and hip (8.8 %, p = 0.044), whereas in patients ≥50 years BMD did not decrease significantly. Introduction The results of studies which addressed the impact of inhaled corticosteroid (ICS) therapy on BMD of patients with asthma are conflicting. This case-control study aimed to compare BMD status in ICS user with asthma with healthy controls according to age. Methods BMD at the lumbar spine (LS), femoral neck (FN) was measured by dual energy X-ray absorptiometry (DEXA). Patients and controls were compared according to BMD gr/cm2, BMD T-score, BMD Z-score, frequency of osteoporosis (defined as BMD T-score ≤−2.5), and frequency of patients with BMD Z-score Results Forty-four ICS user patients (females 63.6 %) with median treatment duration of 6.5 years and 50 controls (females, 69.4 %) with respective mean age of 49.2 ± 9.5 and 47.4 ± 10.5 years (p = 0.38 and p = 0.35) entered the study. Overall LS-BMD and FN-BMD gr/cm2 in total patients were lower than in controls by 6 % (p = 0.065) and 5.9 % (p = 0.09), respectively. In patients 2 was lower than controls by 11.3 % (p = 0.013) and FN-BMD by 8.8 % (p = 0.044). Mean BMD T-score and BMD Z-score in both measurement sites were also lower than controls (p = 0.013 and 0.01, respectively. Frequency of osteoporosis did not differ but frequency of patients with BMD Z-score p = 0.004). In age group ≥50 years old, reduction of BMD in both measurement sites did not reach to a significant level. Conclusion This study indicates that BMD reduction in ICS user with asthma is dependent on age and appears that younger patients are at greater risk of BMD loss. These findings suggest preventive measures particularly in patients
    Osteoporosis International 04/2015; DOI:10.1007/s00198-015-3089-y · 4.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Associations of inhaled corticosteroids (ICS) with bone mineral density (BMD) loss have not been characterized consistently. Objective This randomized, double-blind study assessed effects of mometasone furoate (MF) administered via dry powder inhaler on BMD of patients with persistent asthma. Methods Adults with mild-moderate persistent asthma who did not receive ICS for ≥3 months were randomized to MF 400 μg once daily (QD) in the evening (pm), MF 200 μg QD pm, montelukast sodium (ML) 10 mg QD pm, or fluticasone propionate (FP) 250 μg twice daily. Included patients had 25-hydroxy vitamin D levels ≥15 ng/mL at baseline. All the patients received calcium and vitamin D supplements for daily use during the trial. Duplicate BMD scans were done at baseline, 6 months, and 1 year. The mean percentage change in lumbar spine (LS) BMD from baseline to end point for MF 400 μg versus ML 10 mg was the primary analysis. Changes from baseline in left total femur BMD and femoral neck BMD were secondary assessments. Results At the end point, mean LS BMD increased 0.9% (MF 400 μg), 1.2% (ML), 0.7% (MF 200 μg), and 1.1% (FP), with no significant differences for MF 400 μg versus ML (−0.3% [95% CI, −1.01 to 0.27]) for LS BMD. No significant differences among treatments occurred for changes in left total femur BMD; all were slight increases. Changes in femoral neck BMD were 0.4% (MF 400 μg), −0.2% (ML), −0.2% (MF 200 μg), and −0.4% (FP); only the difference between MF 400 μg and FP was statistically significant (P = .044). Conclusion No detrimental effects on lumbar BMD were observed after up to 1 year of treatment with MF in comparison with ML for patients who received calcium and vitamin D supplements.
    11/2013; 1(6):649–655.e1. DOI:10.1016/j.jaip.2013.07.011